Brawn Biotech Share Price

Overview 

Brawn Biotech Limited is a micro‑cap company engaged in the marketing and distribution of critical care and biotechnology products, as well as trading in general merchandise. Headquartered in Mumbai, Maharashtra, the company was incorporated in 1991 and was formerly known as Brawn Pharmaceuticals Limited before changing its name to Brawn Biotech Limited in November 2010. The Brawn Biotech share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries. 

Market sentiment around the Brawn Biotech stock price often mirrors shifts in demand for critical care and biotechnology products, raw material price volatility, and investor views on the prospects for small‑cap trading firms. Factors such as the company’s ability to secure supply contracts, manage working capital, and government policies on pharmaceutical import duties influence near‑term valuation and medium‑term earnings forecasts. All these factors must be closely monitored to have an idea about the Brawn Biotech share price movements. 

The Brawn Biotech live share price provides real‑time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Brawn Biotech live price helps observe short‑term price fluctuations and understand how the stock is moving in relation to the broader market. 

Furthermore, monitoring the Brawn Biotech share price today helps investors understand real‑time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short‑term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook. The Brawn Biotech stock price remains sensitive to pharmaceutical sector trends. Brawn Biotech share price movements are closely tied to the healthcare distribution industry’s performance. 

Brawn Biotech Limited Company Fundamentals 

A. Company Background

Brawn Biotech Limited was incorporated in 1991. The company’s registered office is located in Mumbai, Maharashtra, India. The company was formerly known as Brawn Pharmaceuticals Limited and changed its name to Brawn Biotech Limited in November 2010. Brawn Biotech is engaged in the marketing and distribution of critical care and biotechnology products, as well as trading in general merchandise. As a micro‑cap entity, it operates in a competitive environment within the pharmaceutical trading and distribution sector. The company is listed on the Bombay Stock Exchange (BSE) under the scrip code 530207. 

B. Product Lines 

• Critical care pharmaceutical products 

• Biotechnology products 

• General merchandise trading 

• Pharmaceutical distribution and marketing 

C. Company Revenue Model 

• Primary revenue from marketing and distribution of critical care and biotechnology products. 

• Volume‑driven revenue based on the quantity of pharmaceutical products distributed. 

• Pricing determined by raw material costs and market demand, affecting overall revenue generation. 

• Revenue from trading of general merchandise. 

• Focus on maintaining relationships with healthcare institutions for product supply. 

• Seasonal variations in demand for critical care products affecting revenue patterns. 

• Government policy changes on pharmaceutical import duties and GST influencing revenue stability. 

D. Geographic Presence 

• Headquartered in Mumbai, Maharashtra, India. 

• Operations focused on the domestic Indian pharmaceutical distribution market. 

• Serves customers across multiple states within India. 

E. Key Milestones 

• 1991 – Company incorporated. 

• 2010 – Name changed from Brawn Pharmaceuticals Limited to Brawn Biotech Limited in November. 

• Year – Listed on the Bombay Stock Exchange (BSE) under scrip code 530207. 

F. Industry Perspective

Brawn Biotech operates in the pharmaceutical distribution and trading industry. India’s pharmaceutical market was valued at USD 50 billion in 2024 and is projected to reach USD 130 billion by 2030, growing at a CAGR of 15‑17%. The critical care segment is a niche but growing area within the broader pharmaceutical market. The biotechnology products market is also expanding rapidly. The distribution sector plays a crucial role in the pharmaceutical supply chain, connecting manufacturers with hospitals and pharmacies. Key drivers include rising healthcare spending, increasing demand for critical care medicines, and the expansion of hospital infrastructure in smaller cities. Challenges facing the industry include intense competition from large pharmaceutical distributors, price regulation, working capital requirements, and the need for cold‑chain logistics for certain biotechnology products. 

Brawn Biotech Limited Stock Market Presence: Listings & Index Representation 

Brawn Biotech is listed on the Bombay Stock Exchange (BSE) under the scrip code 530207. The company is not listed on the National Stock Exchange (NSE). The ISIN for the company is INE899B01015. Its listing on the BSE ensures that the Brawn Biotech share price is accessible to a specific investor base. The company forms part of the BSE SmallCap index and is included in the BSE AllCap index. Being part of the BSE SmallCap index provides a benchmark for investors to compare the company’s performance against other small‑cap companies in the pharmaceutical trading sector. However, the company’s inclusion in major indices is limited, reflecting its micro‑cap status. 

Brawn Biotech Limited Stock Performance and Share Price History 

The performance and share price history of Brawn Biotech Limited are influenced by a mix of operational, macroeconomic, and sectoral factors. A primary driver is the fluctuation in demand for critical care and biotechnology products, as any slowdown directly impacts the Brawn Biotech share price. Government policies regarding pharmaceutical import duties also play a critical role. 

Another major factor is competition from both large pharmaceutical distributors and unorganised players, which can alter long‑term demand projections and influence the Brawn Biotech share price. Quarterly financial results, especially net profit and revenue figures, cause immediate swings in the Brawn Biotech stock price. Additionally, broader market trends and even seasonal demand for critical care products contribute to volatility. Historically, the Brawn Biotech share price has shown sharp declines during phases of weak healthcare demand but has also seen occasional rallies during periods of strong pharmaceutical sales. 

The 52‑week high of the stock is largely dictated by sentiment shifts and external shocks. When demand for critical care products is robust and the company reports strong operational performance, the Brawn Biotech share price tends to rally toward its 52‑week high; conversely, a drop in healthcare spending can drive the Brawn Biotech share price down to a new low. The Brawn Biotech share price also hits its peak when management announces new supply contracts, while a sharp spike in raw material costs pushes the Brawn Biotech share price toward the yearly bottom. Broader market sell‑offs, such as during economic uncertainty, often drag the Brawn Biotech share price to multi‑month lows, even if fundamentals are stable. Conversely, a bullish narrative on healthcare growth can lift the Brawn Biotech share price to a new 52‑week high. Additionally, quarterly earnings misses have historically pressured the Brawn Biotech share price to test its lowest levels. 

The Brawn Biotech share price has exhibited significant volatility over the past decade. The Brawn Biotech share price recorded a 1‑year return that has been negative as of 2026. The Brawn Biotech share price reached a 52‑week high of ₹24.35‑24.37 and a 52‑week low of ₹15.70‑16.15, indicating a wide trading range. The Brawn Biotech share price has a market capitalisation of approximately ₹5.4‑6.48 crore. The Brawn Biotech share price has a beta of 0.11 to 0.13, indicating a low correlation with the broader market. 

The Brawn Biotech stock price has been particularly responsive to quarterly earnings releases. When the company reported gross sales of ₹13.47 crore and a profit after tax of -₹1.80 crore in the latest FY, the Brawn Biotech stock price showed a muted reaction. The Brawn Biotech stock price has shown a pattern of volatility in years when the company’s earnings were inconsistent. The Brawn Biotech stock price has shown a market capitalisation that has fluctuated between approximately ₹5.4 crore and ₹6.5 crore in recent quarters. 

The Brawn Biotech share price reached its 52‑week high before declining, reflecting the volatility inherent in the micro‑cap pharmaceutical distribution space. The Brawn Biotech share price has shown a year‑to‑date return that has been moderate as of early 2026. Comprehending these patterns in the Brawn Biotech share price is instrumental for investors seeking to contextualise long‑term performance trends, as the Brawn Biotech stock price movements illustrate how pharmaceutical distribution industry fundamentals, raw material cycles, and investor expectations converge in market pricing. 

Brawn Biotech Limited Investor Relevance and Role in Portfolio 

Brawn Biotech holds a negligible position for portfolio investors due to its negative earnings and micro‑cap status. The company’s operations in pharmaceutical distribution align it loosely with investment strategies that value healthcare themes, but the negative earnings make it unsuitable for serious portfolios. The Brawn Biotech share price often mirrors how speculative themes resonate with high‑risk investor portfolios. 

Institutional stakeholders play a role in Brawn Biotech’s ownership profile. Promoter holding stands at 52.94% as of March 2026, a slight decrease from 53.39% in the previous quarter. Mutual funds hold 0% stake. Foreign Institutional Investors (FII) hold 0%, Domestic Institutional Investors (DII) hold 0%, and Insurance companies hold 0%. The retail public holds approximately 47.06% stake. The company has reported a negative ROE for 3 consecutive years. 

Based on data, Brawn Biotech exhibits varying levels of beta and volatility across different time horizons. Based on data, the long‑term beta of Brawn Biotech stands at 0.11 to 0.13, indicating that the stock has a very low correlation with the broader market. Based on data, the weekly volatility has been reported as moderate. The Brawn Biotech stock price has shown periods of heightened responsiveness to sector‑specific news regarding pharmaceutical prices and healthcare demand. The Brawn Biotech share price’s beta reflects that the company’s micro‑cap status makes it subject to company‑specific factors rather than broad market trends. The Brawn Biotech share price has historically moved on raw material price announcements. 

Brawn Biotech Limited Sectoral Relevance and Peer Positioning 

The sector relevance of Brawn Biotech is minimal due to its negative earnings and micro‑cap status. Competitors in the pharmaceutical distribution segment include companies such as Apollo Hospitals Enterprise Ltd (pharmacy division), MedPlus Health Services Ltd, and other small‑cap pharmaceutical distributors. Firms with parallels in operational scale are often referenced when evaluating relative performance. 

In valuation terms, factors like the Brawn Biotech P/E ratio have shown negative values due to negative earnings. The current P/E ratio is not applicable (N/A) as TTM earnings are negative. Gross sales for the latest fiscal year were ₹13.47 crore, with a profit after tax of -₹1.80 crore. The Brawn Biotech EPS has been negative in recent periods. The Brawn Biotech market cap has fluctuated between approximately ₹5.4 crore and ₹6.5 crore over the past few years, in line with investor perceptions of the company’s growth potential in the pharmaceutical distribution market. 

The Brawn Biotech earnings over the past few years have been characterised by negative profitability. The company has spent less than 1% of its operating revenues towards interest expenses and 8.36% towards employee cost. The Brawn Biotech share price has been influenced by these valuation metrics. The Brawn Biotech stock price remains speculative, driven more by sentiment than by underlying fundamentals. 

Summary 

Brawn Biotech is a micro‑cap pharmaceutical distribution company listed on the BSE, where the Brawn Biotech share price reflects pharmaceutical price fluctuations, healthcare demand cycles, and small‑cap market sentiment. Its inclusion in the BSE SmallCap index supports limited visibility, while investor interest is shaped by earnings trends and broader healthcare distribution themes. However, the company’s negative earnings and small scale remain significant concerns.